Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects. Academic Press,
pp 219– 225
Ottersen T, Rosenqvist E, Turner CE (1977) The crystal and molecular structure of cannabidiol.
Acta Chem Scand B31:807– 812
Patel RR, Barbosa C, Brustovetsky T, Brustovetsky N, Cummins TR (2016) Aberrant
epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol.
Brain 139:2164– 2181
Perez-Reyes M, Wingfield M (1974) CAnnabidiol and electroencephalographic epileptic activity.
JAMA 230:1635
Pertwee RG, Ross RA, Craib SJ, Thomas A (2002) (-)-Cannabidiol antagonizes cannabinoid
receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456:99– 106
Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC (1998) Complex pharmacology of
natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and
antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci 63:Pl1– 6
Petrzilka T, Haefliger W, Sikemeier C, Ohloff G, Eschenmoser A (1967) Synthese und Chiralität
des (-)-Cannabidiols Vorläufige Mitteilung. Helv Chim Acta 50:719– 723
Reggio PH, Panu AM, Miles S (1993) Characterization of a region of steric interference at the
cannabinoid receptor using the active analog approach. J Med Chem 36:1761– 1771
GW Pharmaceuticals Press Release (2016a) GW pharmaceuticals announces positive phase 3
pivotal study results for epidiolex® (cannabidiol), http://www.gwpharm.com/GW%20
Pharmaceuticals%20Announces%20Positive%20Phase%203%20Pivotal%20Study%20Results
%20for%20Epidiolex%20cannabidiol.aspx
GW Pharmaceuticals Press Release (2016b) GW pharmaceuticals announces positive phase 3
pivotal trial results for epidiolex®(cannabidiol) in the treatment of lennox-gastaut syndrome,
http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Positive%20Phase%
203%20Pivotal%20Trial%20Results%20for%20Epidiolex%20cannabidiol%20in%20the%20
Treatment%20of%20Lennox-Gastaut%20Syndrome.aspx
GW Pharmaceuticals Press Release (2016c) GW pharmaceuticals announces second positive phase
3 pivotal trial for epidiolex (cannabidiol) in the treatment of lennox-gastaut syndrome,http://
http://www.gwpharm.com/PR260916.aspx
Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho
WM, Akamine AT, Almeida VI, Quevedo J, Dal-Pizzol F, Hallak JE, Zuardi AW, Crippa JA,
Palermo-Neto J (2012) Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases
inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor.
Eur J Pharmacol 678:78– 85
Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B (2009) Cannabidiol targets mitochondria
to regulate intracellular ca 2 + levels. J Neurosci 29:2053– 2063
Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, Elebring T, Nilsson K,
Drmota T, Greasley PJ (2007) The orphan receptor GPR55 is a novel cannabinoid receptor.
Br J Pharmacol 152:1092– 1101
Shirazi-zand Z, Ahmad-Molaei L, Motamedi F, Naderi N (2013) The role of potassium BK
channels in anticonvulsant effect of cannabidiol in pentylenetetrazole and maximal
electroshock models of seizure in mice. Epilepsy Behav 28:1– 7
Stiedl O, Pappa E, Konradsson-GeukenÅ,Ögren SO (2015) The role of the serotonin receptor
subtypes 5-HT(1A) and 5-HT(7) and its interaction in emotional learning and memory.
Frontiers Pharmacol 6:162
Sylantyev S, Jensen TP, Ross RA, Rusakov DA (2013) Cannabinoid- and lysophosphatidylinositol-
sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad
Sci USA 110:5193– 5198
Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y, Morimoto S (2007)
Cannabidiolic-acid synthase, the chemotype-determining enzyme in thefiber-type Cannabis
sativa. FEBS Lett 581:2929– 2934
Thomas BF, Compton DR, Martin BR, Semus SF (1991) Modeling the cannabinoid receptor: a
three-dimensional quantitative structure-activity analysis. Mol Pharmacol 40:656– 665
260 B.F. Thomas